Managed Care Cast

One of the most common causes of liver disease in the United States is nonalcoholic fatty liver disease, affecting between 30% and 40% of adults, according to the National Institute of Diabetes, and Digestive and Kidney Diseases. It’s a condition in which excess fat is stored in the liver—a buildup that is not caused by heavy alcohol use. Despite how common nonalcoholic fatty liver disease (NAFLD) is, there are currently no approved medications on the market. In this podcast, we talk to a clinician involved with a program that uses lifestyle management and a patient advocate, who is trying to shape policy to help patients with NAFLD and its more extreme version, nonalcoholic steatohepatitis (NASH). Read more about NAFLD and NASH: Studies Point to Empagliflozin as First Choice for Fatty Liver Disease in T2D: https://www.ajmc.com/newsroom/studies-point-to-empagliflozin-as-first-choice-for-fatty-liver-disease-in-t2d Drug Approvals That Dr Aimee Tharaldson Is Keeping an Eye on for 2019: https://www.ajmc.com/con